Literature DB >> 14765992

Epigenetic regulation of inhibin alpha-subunit gene in prostate cancer cell lines.

P Balanathan1, E M A Ball, H Wang, S E Harris, A N Shelling, G P Risbridger.   

Abstract

Inhibin was first identified as a gonad-derived regulator of pituitary FSH; however, it has subsequently been shown to be a tumour suppressor in the gonad and adrenal glands. Whereas non-malignant regions of human primary prostate carcinomas express inhibin alpha-subunit (INHA), malignant tissues lack INHA transcript and protein, which is consistent with epigenetic regulation of the inhibin alpha-subunit gene (INHA) promoter. This study investigated whether methylation of the INHA promoter was responsible for inactivation of INHA transcription and translation in the prostate cancer cell lines, LNCaP, DU145 and PC3. Methylation of the promoter was revealed by bisulphite genomic sequencing and use of inhibitors of methylation and histone deacetylation resulted in reactivation of the INHA transcription and translation. Significant (P<0.05) downregulation of a luciferase reporter gene downstream from a methylated INHA promoter compared with unmethylated INHA promoter occurred in vitro. The data demonstrate that promoter methylation is associated with downregulation of the INHA gene in prostate cancer cell lines, which is consistent with its tumour suppressive role. Therefore INHA has a significant role in prostate tumorigenesis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14765992     DOI: 10.1677/jme.0.0320055

Source DB:  PubMed          Journal:  J Mol Endocrinol        ISSN: 0952-5041            Impact factor:   5.098


  7 in total

1.  DNA methylation and histone modifications are associated with repression of the inhibin α promoter in the rat corpus luteum.

Authors:  Kristen M Meldi; Georgia A Gaconnet; Kelly E Mayo
Journal:  Endocrinology       Date:  2012-08-03       Impact factor: 4.736

2.  Estrogen receptor-beta activated apoptosis in benign hyperplasia and cancer of the prostate is androgen independent and TNFalpha mediated.

Authors:  Stephen J McPherson; Shirin Hussain; Preetika Balanathan; Shelley L Hedwards; Birunthi Niranjan; Michael Grant; Upeksha P Chandrasiri; Roxanne Toivanen; Yuzhuo Wang; Renea A Taylor; Gail P Risbridger
Journal:  Proc Natl Acad Sci U S A       Date:  2010-02-01       Impact factor: 11.205

3.  Hypoxia-induced inhibin promotes tumor growth and vascular permeability in ovarian cancers.

Authors:  Shrikant Pradhan; Roohi Chaudhary; Ben Horst; Eduardo Listik; Liz Quintero-Macias; Alex Seok Choi; Michael Southard; Yingmiao Liu; Regina Whitaker; Nadine Hempel; Andrew Berchuck; Andrew B Nixon; Nam Y Lee; Yoav I Henis; Karthikeyan Mythreye
Journal:  Commun Biol       Date:  2022-06-02

4.  Vinclozolin exposure in utero induces postpubertal prostatitis and reduces sperm production via a reversible hormone-regulated mechanism.

Authors:  Prue A Cowin; Elspeth Gold; Jasna Aleksova; Moira K O'Bryan; Paul M D Foster; Hamish S Scott; Gail P Risbridger
Journal:  Endocrinology       Date:  2010-01-07       Impact factor: 4.736

5.  DNA promoter methylation-dependent transcription of the double C2-like domain β (DOC2B) gene regulates tumor growth in human cervical cancer.

Authors:  Shama Prasada Kabekkodu; Samatha Bhat; Raghu Radhakrishnan; Abhijit Aithal; Roshan Mascarenhas; Deeksha Pandey; Lavanya Rai; Pralhad Kushtagi; Gopinath Puthiya Mundyat; Kapaettu Satyamoorthy
Journal:  J Biol Chem       Date:  2014-02-25       Impact factor: 5.157

6.  Elevated level of inhibin-alpha subunit is pro-tumourigenic and pro-metastatic and associated with extracapsular spread in advanced prostate cancer.

Authors:  P Balanathan; E D Williams; H Wang; J S Pedersen; L G Horvath; M G Achen; S A Stacker; G P Risbridger
Journal:  Br J Cancer       Date:  2009-05-12       Impact factor: 7.640

7.  Early-onset endocrine disruptor-induced prostatitis in the rat.

Authors:  Prue A Cowin; Paul Foster; John Pedersen; Shelley Hedwards; Stephen J McPherson; Gail P Risbridger
Journal:  Environ Health Perspect       Date:  2008-07       Impact factor: 9.031

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.